Brookfield Renewable Partners (BEP) financials
- Dec 2025
Price
Performance +0.7% 1Y
1Y: $28.33 on 22 Oct 2025 → $28.54. High $37.31 (28 May 2026), low $26.67 (18 Dec 2025).
- Previous close
- $28.91
- 52-week range
- $26.67 – $37.31
- One year
- −0.24%
Overview
- Symbol
- BEP
- Sector
- Utilities
- Industry
- Electric Services
- Exchange
- US
- Currency
- USD
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 16,897 | — | — | — | 37,825 | 46,149 | 58,353 | 63,727 |
| Fixed assets | 38,177 | 41,055 | 44,590 | 49,432 | 54,283 | 64,005 | 73,475 | 70,456 |
| Total assets | 43,508 | 46,196 | 49,722 | 55,867 | 64,111 | 76,128 | 94,809 | 98,701 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,286 | 1,554 | 1,296 | 734 | 1,711 | 1,865 | 1,274 | 1,147 |
| Cash from investing | -1,077 | -1,211 | -382 | -2,544 | -5,066 | -4,356 | -6,800 | -8,647 |
| Cash from financing | -684 | -402 | -792 | 2,143 | 3,489 | 2,596 | 7,649 | 6,418 |
| Net cash flow | -497 | -65 | 136 | 298 | 106 | 143 | 2,028 | — |
| Capital expenditure | -271 | -460 | -447 | -1,967 | -2,190 | -2,809 | -3,733 | -6,587 |
| Free cash flow | 1,015 | 1,094 | 849 | -1,233 | -479 | -944 | -2,459 | -5,440 |
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of BEP filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Brookfield Renewable Partners L.P.
Free account. Everything above stays public.
Write why you follow Brookfield Renewable Partners L.P. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
